Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 1 13Phase 3 7Phase 1/2 7Phase NA 5Phase EARLY_PHASE1 2Phase 4 2Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1

Conditions

Breast Neoplasms 276Neoplasms 202Prostatic Neoplasms 118Polycystic Ovary Syndrome 114Colorectal Neoplasms 103Carcinoma, Hepatocellular 103Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Stomach Neoplasms 62Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Pain 59Neoplasm Metastasis 54Multiple Myeloma 52Pancreatic Neoplasms 46Keratosis, Actinic 46Head and Neck Neoplasms 43Pain, Postoperative 42Leukemia, Myeloid, Acute 40Leiomyoma 39Recurrence 38Liver Neoplasms 38Colonic Neoplasms 37Uterine Cervical Neoplasms 35Lymphoma 35Brain Neoplasms 34Infertility 33Papillomavirus Infections 32Ovarian Neoplasms 31Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30

Interventions

arginyllysine 1Octreotide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Carcinoid Tumor × Clear all
NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Advanced Accelerator Applications

Phase 4 Completed
42 enrolled 11 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡